146 related articles for article (PubMed ID: 33338269)
1. Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
Koomen JV; Stevens J; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan DE; Makino H; McMurray JJV; Parving HH; Perkovic V; Tobe SW; de Zeeuw D; Heerspink HJL
Clin Pharmacol Ther; 2021 Jun; 109(6):1631-1638. PubMed ID: 33338269
[TBL] [Abstract][Full Text] [Related]
2. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL; Parving HH; Andress DL; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Melnick JZ; Miller MG; Pergola PE; Perkovic V; Tobe S; Yi T; Wigderson M; de Zeeuw D;
Lancet; 2019 May; 393(10184):1937-1947. PubMed ID: 30995972
[TBL] [Abstract][Full Text] [Related]
3. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
Heerspink HJL; Andress DL; Bakris G; Brennan JJ; Correa-Rotter R; Dey J; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray J; Perkovic V; Tobe S; Wigderson M; Parving HH; de Zeeuw D
Diabetes Obes Metab; 2018 Jun; 20(6):1369-1376. PubMed ID: 29405626
[TBL] [Abstract][Full Text] [Related]
4. Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease.
Smeijer JD; Koomen JV; Kohan DE; McMurray JJV; Bakris GL; Correa-Rotter R; Hou FF; Kitzman DW; Makino H; Mayer G; Nowicki M; Perkovic V; Rossing P; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
Clin Pharmacol Ther; 2022 Nov; 112(5):1098-1107. PubMed ID: 35892316
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A
Waijer SW; Gansevoort RT; Bakris GL; Correa-Rotter R; Hou FF; Kohan DE; Kitzman DW; Makino H; McMurray JJV; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
Clin J Am Soc Nephrol; 2021 Dec; 16(12):1824-1832. PubMed ID: 34853062
[TBL] [Abstract][Full Text] [Related]
6. Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.
Koomen JV; Stevens J; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Parving HH; Perkovic V; Tobe SW; de Zeeuw D; Heerspink HJL
Diabetes Obes Metab; 2021 Feb; 23(2):561-568. PubMed ID: 33184931
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.
Schievink B; de Zeeuw D; Smink PA; Andress D; Brennan JJ; Coll B; Correa-Rotter R; Hou FF; Kohan D; Kitzman DW; Makino H; Parving HH; Perkovic V; Remuzzi G; Tobe S; Toto R; Hoekman J; Lambers Heerspink HJ
Eur J Prev Cardiol; 2016 May; 23(7):758-68. PubMed ID: 26229089
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
Zhou Y; Chi J; Huang Y; Dong B; Lv W; Wang YG
Diabet Med; 2021 Jan; 38(1):e14411. PubMed ID: 33000477
[TBL] [Abstract][Full Text] [Related]
9. Baseline characteristics and enrichment results from the SONAR trial.
Heerspink HJL; Andress DL; Bakris G; Brennan JJ; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray J; Perkovic V; Tobe S; Wigderson M; Yi T; Parving HH; de Zeeuw D
Diabetes Obes Metab; 2018 Aug; 20(8):1829-1835. PubMed ID: 29604160
[TBL] [Abstract][Full Text] [Related]
10. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.
Smeijer JD; Koomen J; Kohan DE; McMurray JJV; Bakris GL; Correa-Rotter R; Hou FF; Januzzi JL; Kitzman DW; Kolansky DM; Makino H; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
JACC Heart Fail; 2022 Jul; 10(7):498-507. PubMed ID: 35772861
[TBL] [Abstract][Full Text] [Related]
11. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
Heerspink HJL; Xie D; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Perkovic V; Rossing P; Parving HH; de Zeeuw D;
J Am Soc Nephrol; 2021 Nov; 32(11):2900-2911. PubMed ID: 34551995
[TBL] [Abstract][Full Text] [Related]
12. Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight.
Koomen JV; Stevens J; Mostafa NM; Parving HH; de Zeeuw D; Heerspink HJL
Diabetes Obes Metab; 2018 Aug; 20(8):2019-2022. PubMed ID: 29603851
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.
Smeijer JD; Kohan DE; Rossing P; Correa-Rotter R; Liew A; Tang SCW; de Zeeuw D; Gansevoort RT; Ju W; Lambers Heerspink HJ
Cardiovasc Diabetol; 2023 Sep; 22(1):251. PubMed ID: 37716952
[TBL] [Abstract][Full Text] [Related]
14. Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
Chan KW; Smeijer JD; Schechter M; Jongs N; Vart P; Kohan DE; Gansevoort RT; Liew A; Tang SCW; Wanner C; de Zeeuw D; Heerspink HJL
Kidney Int; 2023 Dec; 104(6):1219-1226. PubMed ID: 37657768
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.
Kohan DE; Lambers Heerspink HJ; Coll B; Andress D; Brennan JJ; Kitzman DW; Correa-Rotter R; Makino H; Perkovic V; Hou FF; Remuzzi G; Tobe SW; Toto R; Parving HH; de Zeeuw D
Clin J Am Soc Nephrol; 2015 Sep; 10(9):1568-74. PubMed ID: 26153128
[TBL] [Abstract][Full Text] [Related]
16. Comparison of exposure response relationship of atrasentan between North American and Asian populations.
Heerspink HJ; Makino H; Andress D; Brennan JJ; Correa-Rotter R; Coll B; Davis JW; Idler K; Kohan DE; Liu M; Perkovic V; Remuzzi G; Tobe SW; Toto R; Parving HH; de Zeeuw D
Diabetes Obes Metab; 2017 Apr; 19(4):545-552. PubMed ID: 27981738
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.
Webb DJ; Coll B; Heerspink HJL; Andress D; Pritchett Y; Brennan JJ; Houser M; Correa-Rotter R; Kohan D; Makino H; Perkovic V; Remuzzi G; Tobe SW; Toto R; Busch R; Pergola P; Parving HH; de Zeeuw D
Drugs R D; 2017 Sep; 17(3):441-448. PubMed ID: 28831752
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).
Andress DL; Coll B; Pritchett Y; Brennan J; Molitch M; Kohan DE
Life Sci; 2012 Oct; 91(13-14):739-42. PubMed ID: 22326504
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic transformation for diabetic kidney disease.
Tuttle KR; Cherney DZI
Kidney Int; 2021 Feb; 99(2):301-303. PubMed ID: 33509348
[TBL] [Abstract][Full Text] [Related]
20. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.
de Zeeuw D; Coll B; Andress D; Brennan JJ; Tang H; Houser M; Correa-Rotter R; Kohan D; Lambers Heerspink HJ; Makino H; Perkovic V; Pritchett Y; Remuzzi G; Tobe SW; Toto R; Viberti G; Parving HH
J Am Soc Nephrol; 2014 May; 25(5):1083-93. PubMed ID: 24722445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]